Chordia Therapeutics Inc.
26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-0012 Japan
info@chordiatherapeutics.com<Press Release>
May 19, 2022
Chordia Therapeutics Concludes Basic Agreement on Business Tie up
with MEDIPAL HOLDINGS CORPORATION
Kanagawa, Japan, May 19, 2022 – Chordia Therapeutics Inc. (“Chordia”), a biotech
company engaged in the research and development of novel therapies for cancers, today
announced that it signed a basic agreement on collaboration with MEDIPALHOLDINGS CORPORATION (“MEDIPAL”) on May 13, 2022.
Based on the basic agreement of this collaboration, the two companies will proceedwith specific discussions toward the alliance. Chordia believes that MEDIPAL’s
distribution network in Japan and various sales promotion functions such as RDMR*1 and Clinical Cloud by MEDIPAL*2 will greatly contribute to Chordia’s
market penetration when marketing its drugs currently under development in Japan.
Chordia expects that this collaboration will contribute to delivering new treatment
methods to patients.
*1 RD-MR (Rare Disease MRs): A designation within MEDIPAL given toMSs (Marketing Specialists of pharmaceutical wholesalers) andpharmacists who have passed the MR certification exam and are engaged
in information provision activities focused on rare diseases.
*2 Clinical Cloud by MEDIPAL: An information provision platform forhealthcare professionals provided by MEDIPAL.

About MEDIPAL HOLDINGS CORPORATION
Established:
May 1923
Business Description: As a holding company, MEDIPAL HOLDINGS controls,
administers and supports the operating activities of companies
in which it holds shares in the Prescription Pharmaceutical
Wholesale Business; the Cosmetics, Daily Necessities and OTC
Pharmaceutical Wholesale Business; and the Animal Health
Products and Food Processing Raw Materials Wholesale
Business, and conducts business development for theMEDIPAL Group.
Location:
2-7-15, Yaesu, Chuo-ku, Tokyo 104-8461 Japan
Representative:
Shuichi Watanabe, Representative Director,President and CEOWebsite:
https://www.medipal.co.jp/english/
About Chordia Therapeutics
Chordia was established in November 2017 at Shonan Health Innovation Park(“Shonan iPark”) in Fujisawa, Kanagawa Prefecture, as a biotech company engaged inChordia Therapeutics Inc.
26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-0012 Japan
info@chordiatherapeutics.com

the research and development of novel therapies for cancers, with the goal ofresearching and developing first-in-class anti-cancer drugs and creating innovative
new drugs.
The CLK inhibitor CTX-712, which is currently under development as the leadprogram, is currently undergoing Phase I clinical trials in Japan for patients withadvanced, relapsed, or refractory malignancies. CTX-712 targets vulnerabilities
resulting from RNA deregulation, which has been identified as a new hallmark ofcancer, and is expected to be an effective therapeutic agent.
In addition to its leading program for CTX-712, Chordia is engaged in the research ofseveral developments in our pipeline, including CTX-439, a CDK12 inhibitor, whichis expected to be effective in cancers with specific abnormalities, as well as GCN2inhibitors.
Established:
Address:
Representative:
Website:November 2017
26-1, Muraoka-Higashi 2 chome, Fujisawa,
Kanagawa 251-0012, Japan
Hiroshi Miyake, Representative Director
https://www.chordiatherapeutics.com/en/

For more information, contact Kentaro Kume, IR: info@chordiatherapeutics.com